Testing effectiveness (Phase 2)Study completedNCT00383760
What this trial is testing
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
Who this might be right for
Adenocarcinoma of the PancreasPancreatic CancerRecurrent Pancreatic Cancer+3 more
National Cancer Institute (NCI) 15